Advertisement
Screener

OMEROS CORP (OMER) Overview

OMEROS CORP (OMER) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.15; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 0.62; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.47; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.43; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$5.97$7.75$10.07$13.09$17.01$22.102025-11-062026-11-06$1.03$1.90$3.50$6.47$11.96$22.102021-11-082026-11-06$1.03$1.99$3.85$7.46$14.46$28.022016-11-072026-11-06$1.03$1.99$3.85$7.46$14.46$28.022009-10-082026-11-06$1.03$1.99$3.85$7.46$14.46$28.022009-10-082026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$16.91
Previous close
$19.25
Change
-$2.34
Change (%)
-12.16%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

OMER
+12.05%
S&P 500
(m)

1 year

OMER
+360.53%
S&P 500
(m)

3 years

OMER
+559.25%
S&P 500
(m)

5 years

OMER
+43.66%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.15

-0.66-0.290.070.440.8031 Mar 2025: estimate (m); actual -0.5831 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.4330 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.4730 Sept 2025(m)31 Mar 2026: estimate (m); actual 0.6231 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.1530 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.15(m)(m)
1 Jan 202631 Mar 2026(m)0.62(m)(m)
1 Jul 202530 Sept 2025(m)-0.47(m)(m)
1 Apr 202530 Jun 2025(m)-0.43(m)(m)
1 Jan 202531 Mar 2025(m)-0.58(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.05

-2.78-1.260.261.783.3031 Dec 2021: estimate (m); actual 3.1231 Dec 2021(m)31 Dec 2022: estimate (m); actual 0.7631 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.8831 Dec 2023(m)31 Dec 2024: estimate (m); actual -2.7031 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.0531 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.05(m)(m)
1 Jan 202431 Dec 2024(m)-2.70(m)(m)
1 Jan 202331 Dec 2023(m)-1.88(m)(m)
1 Jan 202231 Dec 2022(m)0.76(m)(m)
1 Jan 202131 Dec 2021(m)3.12(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 28.53M ■ Earnings 13.23M — Profit margin 46.38%

-44.20M45.4%-7.20M219.5%29.80M393.6%66.80M567.7%31 Mar 2025: revenue 0.00M; earnings -33.46M; profit margin (m)31 Mar 202530 Jun 2025: revenue 0.00M; earnings -25.42M; profit margin (m)30 Jun 202531 Mar 2026: revenue 9.89M; earnings 56.06M; profit margin 566.66%31 Mar 202630 Jun 2026: revenue 28.53M; earnings 13.23M; profit margin 46.38%30 Jun 2026

31 Dec 2020 ■ Revenue 73.81M ■ Earnings -138.06M — Profit margin -187.04%

-168.04M-425.4%-64.77M-308.4%38.51M-191.5%141.79M-74.6%31 Dec 2017: revenue 64.83M; earnings -53.48M; profit margin -82.50%31 Dec 201731 Dec 2018: revenue 29.87M; earnings -126.76M; profit margin -424.39%31 Dec 201831 Dec 2019: revenue 111.81M; earnings -84.49M; profit margin -75.57%31 Dec 201931 Dec 2020: revenue 73.81M; earnings -138.06M; profit margin -187.04%31 Dec 2020

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$16.91(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$16.91High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning OMER

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$124.83M
Profit margin
(m)
Return on assets · 12 month
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
175.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.52M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-8.55%*
Total return · month
3.44%*
Total return · quarter
94.25%*
Total return · half year
94.84%*
Total return · year to date
12.05%*
Total return · 1 year
360.53%*
Total return · 3 years
559.25%*
Total return · 5 years
43.66%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

OMEROS CORP Overview

View more →

(m)

(m)

SEC CIK
1285819
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
201 ELLIOTT AVENUE WEST, SEATTLE, Washington, 98119, United States
Fiscal year end
1231
Phone
206-676-5000

Similar stocks

Stock NameCountryMarket CapPE Ratio
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Innoviva, Inc. (INVA)United States$1.493B4.62
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Kardigan, Inc. (KARD)United States$1.346B
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82